MEF2A is a transcription factor for circPVT1 and contributes to the malignancy of acute myeloid leukemia

Kun Wu, Yuntao Li, Bo Nie, Chong Guo, Xiaobo Ma, Linyan Li, Shenju Cheng, Yanhong Li, Shan Luo, Yun Zeng, Jian Yu, Mingxia ShiInternational Journal of Oncology 2024 · DOI

Abstract

Acute myeloid leukemia (AML) is a hematological malignancy characterized by high relapse and poor survival rates. This study investigates the regulatory role of circular RNA circPVT1 and the transcription factor myocyte enhancer factor 2A (MEF2A) in AML progression. Using bioinformatics, dual-luciferase reporter assays, and functional experiments, the researchers identified a novel MEF2A/circPVT1/miR-455-3p/MCL1 axis. The findings reveal that MEF2A drives circPVT1 expression, which then sponges miR-455-3p to upregulate the anti-apoptotic protein MCL1, promoting cell viability and epithelial-mesenchymal transition (EMT) in AML cells.

The Challenge of AML

Acute myeloid leukemia (AML) remains a formidable challenge in oncology, with a five-year survival rate of less than 50%. While genetic mutations are known drivers, the role of non-coding RNAs—specifically circular RNAs (circRNAs)—in the disease's "middle management" is a growing area of interest. circRNAs are stable, loop-shaped molecules that regulate gene expression by acting as molecular "sponges" for microRNAs. This study aimed to map the regulatory hierarchy of circPVT1 in AML, identifying its upstream triggers and downstream effects.

Methods and Validation

The authors employed a multi-layered approach to validate the proposed molecular axis:

  • Bioinformatics: Used JASPAR to predict transcription factor binding sites and StarBase for microRNA targets.
  • Molecular Interaction: Dual-luciferase reporter assays and Argonaute 2-RNA immunoprecipitation (Ago2-RIP) confirmed that these molecules physically interact.
  • Functional Assays: Manipulated gene levels in AML cell lines (NB4 and HL-60) and clinical samples from 42 AML patients to measure impacts on cell viability, apoptosis, and protein expression via Western Blotting.
  • Stability Testing: RNase R treatment confirmed that circPVT1 is a highly stable circular molecule, unlike linear RNAs.

Key Results: Mapping the MEF2A/circPVT1 Axis

MEF2A as an Upstream Trigger

While most research focuses on what circRNAs do, this study identifies MEF2A as the transcription factor that binds to the PVT1 gene promoter to ramp up circPVT1 production.

Dual-luciferase reporter assay confirming MEF2A as a transcription factor for circPVT1.

As shown in the figure above, bioinformatics identified CpG islands in the promoter region (Panel A), and luciferase assays (Panel B) demonstrated a significant increase in fluorescence when MEF2A was co-transfected with the circPVT1 promoter construct, confirming high binding affinity.

The "Sponge" Mechanism and MCL1

The study confirms a competitive endogenous RNA (ceRNA) mechanism where circPVT1 acts as a decoy for miR-455-3p. By soaking up this tumor-suppressing microRNA, circPVT1 effectively shields MCL1, an anti-apoptotic protein. This allows leukemia cells to evade programmed cell death and survive longer.

Promoting Malignancy and EMT

Interestingly, the axis was found to promote markers of Epithelial-Mesenchymal Transition (EMT), such as N-cadherin and Vimentin. While EMT is typically associated with solid tumor metastasis, in AML, it likely contributes to the invasiveness and malignant progression of cells within the bone marrow.

Discussion and Future Directions

The stability of circPVT1 makes it an excellent candidate for a blood-based biomarker, as it resists degradation better than linear RNAs. However, the study has limitations:

  • In Vivo Validation: The research is primarily in vitro. Animal models are needed to confirm if targeting this axis can shrink tumors in a living organism.
  • Network Complexity: miR-455-3p is likely one of many targets for circPVT1, and the full regulatory landscape remains to be fully mapped.
  • Epigenetic Factors: The role of DNA methylation at the identified CpG islands warrants further investigation to understand why this pathway becomes over-activated in AML patients.

Conclusion

MEF2A acts as a critical transcription factor for circPVT1, driving a pathway that promotes AML malignancy through the miR-455-3p/MCL1 axis. Targeting circPVT1 or its upstream regulator MEF2A could offer new therapeutic strategies for treating this aggressive leukemia.

Summary updated

Abstract

Acute myeloid leukemia (AML) is a hematological malignancy with a high relapse rate and a poor survival rate. The circular RNA circPVT1 and myocyte enhancer factor 2A (MEF2A) have unique functions in the progression of AML; however, the underlying mechanisms and clinical significance remain to be clarified. Bioinformatics and database analyses were used to assess the transcription factors and target genes of circPVT1. Dual‑luciferase reporter gene and argonaute 2‑RNA immunoprecipitation assays were used to verify the targeted relationships. The expression levels of related genes and proteins were detected by reverse transcription‑quantitative PCR and western blotting. Cell viability and apoptosis were detected by Cell Counting Kit‑8 assay and flow cytometry, respectively. The results revealed that circPVT1 was highly expressed in AML samples and cell lines, and that MEF2A regulated the expression of circPVT1. MEF2A overexpression promoted cell viability and epithelial‑mesenchymal transition (EMT), and inhibited cell apoptosis. In addition, circPVT1 was revealed to target the regulation of microRNA (miR)‑455‑3p, and miR‑455‑3p targeted the regulation of MCL1 expression, thus indicating that circPVT1 promoted MCL1 expression through its interaction with miR‑455‑3p. Furthermore, cells were transfected with the small interfering RNA‑(si)‑circPVT1, miR‑455‑3p inhibitor or si‑MCL1, and si‑circPVT1 and si‑MCL1 inhibited the viability and EMT of NB4 and HL‑60 cells. However, the miR‑455‑3p inhibitor had the opposite effect on cells. In conclusion, MEF2A may act as a transcription factor of circPVT1 to promote the malignant process of AML, and knockdown of circPVT1 could inhibit the viability and EMT of AML cells through the miR‑455‑3p/MCL1 axis.
BibTeX
@article{wu2024mef,
  author = {Kun Wu and Yuntao Li and Bo Nie and Chong Guo and Xiaobo Ma and Linyan Li and Shenju Cheng and Yanhong Li and Shan Luo and Yun Zeng and Jian Yu and Mingxia Shi},
  title = {{MEF2A is a transcription factor for circPVT1 and contributes to the malignancy of acute myeloid leukemia}},
  journal = {International Journal of Oncology},
  year = {2024},
  doi = {10.3892/ijo.2024.5699},
}
Figure